Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02270814 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma

Study acronym: CACTUX
StatusActive, Not Recruiting
PhasePhase 2
Started2015-02-02
View on ClinicalTrials.gov ↗
The purpose of this research study is to look at the effect of a treatment regimen called CACTUX on head and neck cancer. The CACTUX regimen is a combination of three drugs called cisplatin, nab-paclitaxel, and cetuximab (although carboplatin may be given in place of cisplatin if participants have previously had problems receiving cisplatin). The use of nab-paclitaxel in this combination is different from routine care, in which a drug called 5FU is often given instead, but the investigators group has conducted previous research where the investigators incorporated nab-paclitaxel into routine treatment with cisplatin, 5FU, and cetuximab. The investigators are looking at the incidence of side effects with the CACTUX regimen as well as response of the disease and health status.

Amendment history 5 changes detected by DataLookout

2026-08-29
critical
Primary endpoint(s) modified
WasProgression-free survival (PFS) - with first line therapy
NowProgression-free survival (PFS)
2026-08-29
notable
Primary completion pushed: 2026-05-15 → 2026-09-30
2026-08-29
minor
Completion pushed: 2026-05-15 → 2026-09-30
2026-05-06
minor
Primary completion moved earlier: 2026-06-30 → 2026-05-15
2026-05-06
minor
Completion moved earlier: 2026-06-30 → 2026-05-15
Trial Details
NCT Number NCT02270814
Lead Sponsor Washington University School of Medicine
Collaborators: Celgene Corporation
Conditions Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck
Enrollment 74 participants
Start Date 2015-02-02
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-28